Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Cerebral venous sinus thrombosis (CVST ... cerebral infarction, intracranial hypertension, unstable or deteriorating neurological status (Benamer & Bone, 2000; Ekseth et al., ...

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

Servier Egypt, a leading player in the pharmaceutical industry and part of the global Servier Group, proudly marked its ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Learn more about whether Glaukos Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades ...

Learn more about whether Bausch + Lomb Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Health issues that concern men above the age of 4o the most are related to their energy, stamina, and vitality. Men succumb ...

The heart muscle requires a continuous supply of oxygen and nutrients to function effectively. A heart attack typically ...

The Tadasana or Mountain Pose strengthens the legs, as well as stretches the spine. Here’s how it can help in improving ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...